Marcos Henrique da Silva Mezzari

Marcos Henrique da Silva Mezzari

Auto-generated profile, based on publicly available information

Marcos Henrique da Silva Mezzari

Faculty of Medicine, Federal University of Santa Catarina, Araranguá, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
NLNatan Lucca Lima
Natan Lucca Lima
MMMarcos Henrique da Silva Mezzari
Marcos Henrique da Silva Mezzari
BMBárbara Ghizoni Maggi
Bárbara Ghizoni Maggi
DGDavi Orli Machado Grüdtner
Davi Orli Machado Grüdtner
LRLuiz Pedro Willimann Rogério
Luiz Pedro Willimann Rogério

1 August 2025 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
NLNatan Lucca Lima
Natan Lucca Lima
MMMarcos Henrique da Silva Mezzari
Marcos Henrique da Silva Mezzari
LJLuís Cláudio Izidio Costa Júnior
Luís Cláudio Izidio Costa Júnior
DGDavi Orli Machado Grüdtner
Davi Orli Machado Grüdtner
BMBárbara Ghizoni Maggi
Bárbara Ghizoni Maggi
GIGustavo R. Isolan
Gustavo R. Isolan

20 November 2025 in Journal of Chemotherapy
Verified
Journal Article
Closed access
MMMarcos Henrique da Silva Mezzari
Marcos Henrique da Silva Mezzari
NLNatan Lucca Lima
Natan Lucca Lima
BMBárbara Ghizoni Maggi
Bárbara Ghizoni Maggi
DGDavi Orli Machado Grüdtner
Davi Orli Machado Grüdtner
JSJoão Cândido Spezia de Souza
João Cândido Spezia de Souza
GIGustavo R. Isolan
Gustavo R. Isolan
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.

5 May 2026 in Neurocritical Care
Verified
Journal Article
Closed access
NLNatan Lucca Lima
Natan Lucca Lima
MMMarcos Henrique da Silva Mezzari
Marcos Henrique da Silva Mezzari
JMJosete Mazon
Josete Mazon
GIGustavo R. Isolan
Gustavo R. Isolan

7 August 2026 in Neurosurgery
Verified
Journal Article
Closed access
LBLeonardo de Barros Oliveira Brenner
Leonardo de Barros Oliveira Brenner
RARudolfh Batista Arend
Rudolfh Batista Arend
BPBruno Zilli Peroni
Bruno Zilli Peroni
LCLeonardo Januário Campos Cardoso
Leonardo Januário Campos Cardoso
NLNatan Lucca Lima
Natan Lucca Lima
MLMichael T Lawton
Michael T Lawton
BACKGROUND AND OBJECTIVES: Bypass surgery is an important option for treating complex intracranial aneurysms (IAs) and Moyamoya disease (MMD), particularly when conventional approaches are insufficient. However, the literature remains heterogeneous, with important limitations in reporting quality that hinder reproducibility and comparability. We aimed to evaluate the current evidence and propose a reporting guideline to improve transparency and methodological rigor. METHODS: We searched PubMed, Embase, and Web of Science databases. Eligible studies were observational or randomized studies reporting clinical and/or surgical outcomes of bypass for IAs or MMD, including a sample size of ≥3 patients, and published in English between January 1, 2000, and January 1, 2025. Assessment focused on key domains: (1) Assessment of reported baseline characteristics; (2) assessment and reporting on imaging methods and pathology characteristics; (3) reporting on pivotal concept definitions; (4) reporting on neurosurgeon(s) and staff characteristics; (5) reporting on the anesthetic protocol; (6) reporting on vascular procedure details; (7) reporting on antiaggregant and anticoagulation protocol; (8) assessing and reporting on clinical and surgical outcomes, besides adverse events; (9) reporting on retreatment details; and (10) funding and conflicts of interest declarations. RESULTS: Thirty studies were included. Our assessment revealed substantial reporting gaps across all domains pertinent to bypass. A bypass reporting guideline was developed and organized into 10 domains, featuring a pragmatic checklist composed of one common domain and disease-specific sections for IA and MMD. The guideline emphasizes detailed technical reporting, graft patency assessment and verification, perioperative antithrombotic management, and standardized clinical and radiological outcome measures. CONCLUSION: This systematic review on bypass surgery for IA and MMD identified substantial methodological and reporting limitations that compromise evidence quality and comparability. The proposed reporting guideline provides a structured framework to address these gaps, enhancing transparency, reproducibility, and standardization, with the potential to strengthen the evidence base and improve patient care.

4 February 2026 in Arquivos Catarinenses de Medicina
Verified
Journal Article
Open access
GGGabriel Pettenon Gubert
Gabriel Pettenon Gubert
JAJoão Pedro Kern Alves
João Pedro Kern Alves
MMMarcos Henrique Da Silva Mezzari
Marcos Henrique Da Silva Mezzari
VKVinicius Kenji Koura
Vinicius Kenji Koura
HGHelena Vitali Gava
Helena Vitali Gava
CSCintia Scherer
Cintia Scherer
Introdução: A doença de Crohn é uma doença inflamatória intestinal crônica com curso clínico heterogêneo e potencial para complicações estruturais e manifestações extraintestinais. Dados regionais sobre seu perfil fenotípico e desfechos clínicos no estado de Santa Catarina ainda são escassos. Objetivo: Descrever o perfil fenotípico, as complicações e os fatores associados à atividade da doença em pacientes com doença de Crohn em Santa Catarina. Métodos: Estudo transversal analítico realizado entre março e junho de 2025, com 83 pacientes adultos com diagnóstico de Crohn, recrutados por questionário online validado. Foram coletadas variáveis sociodemográficas, clínicas, terapêuticas e de hábitos de vida. A atividade da doença foi avaliada pelo Índice de Harvey-Bradshaw (HBI). Análises estatísticas incluíram frequências, testes qui-quadrado e regressão logística. Resultados: Predominância do sexo feminino (78,3%) e faixa etária de 20–39 anos (59,0%). Complicações estruturais foram registradas em 55,4% dos casos, sendo fístulas (37,3%) e abscessos (18,1%) as mais frequentes. Manifestações extraintestinais ocorreram em 72,3%, com destaque para artralgia (61,4%). Atividade moderada/grave (HBI ≥8) foi observada em 42,1% dos pacientes e associada significativamente ao tabagismo ativo (p-valor=0,017), sono ruim (p-valor=0,006), ausência de atividade física (p-valor=0,034) e uso de corticoides (p-valor<0,001). O uso de biológicos mostrou efeito protetor (p-valor=0,007). Conclusão: Pacientes com doença de Crohn em Santa Catarina apresentam elevada carga de complicações e atividade da doença associada a fatores comportamentais e terapêuticos modificáveis. Os achados reforçam a necessidade de abordagens integradas e políticas regionais voltadas ao manejo precoce e multidisciplinar.